News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

American Society of Hematology: Secondary Cancers Cloud Myeloma Drug, Roswell Park Cancer Institute Study


12/10/2010 6:34:27 AM

MedPageToday -- ORLANDO -- A popular therapy for multiple myeloma was associated with an excess of new cancers in three different studies presented here. The overall number of secondary malignancies was relatively small -- 44 in more than 800 patients treated with lenalidomide (Revlimid) -- but the results consistently showed a cancer excess compared with patients who received comparator therapies, researchers reported at the American Society of Hematology meeting.

Read at MedPageToday

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES